347 results match your criteria Molecular Targets in the Treatment of Head and Neck Squamous Cell Carcinoma


Targeted molecular imaging of head and neck squamous cell carcinoma: a window into precision medicine.

Chin Med J (Engl) 2020 May 11. Epub 2020 May 11.

Department of Radiology, School of Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, Shanghai 200011, China.

Tumor biomarkers play important roles in tumor growth, invasion, and metastasis. Imaging of specific biomarkers will help to understand different biological activities, thereby achieving precise medicine for each head and neck squamous cell carcinoma (HNSCC) patient. Here, we describe various molecular targets and molecular imaging modalities for HNSCC imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CM9.0000000000000751DOI Listing

Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma.

JNCI Cancer Spectr 2019 Dec 12;3(4):pkz055. Epub 2019 Nov 12.

Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France.

A better understanding of cancer biology has led to the development of molecular targeted therapy, which has dramatically improved the outcome of some cancer patients, especially when a biomarker of efficacy has been used for patients' selection. In head and neck oncology, cetuximab that targets epidermal growth factor receptor is the only targeted therapy that demonstrated a survival benefit, both in the recurrent and in the locally advanced settings, yet without prior patients' selection. We herein review the clinical development of targeted therapy in head and neck squamous cell carcinoma in light of the molecular landscape and give insights in on how innovative clinical trial designs may speed up biomarker discovery and deployment of new molecular targeted therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncics/pkz055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049986PMC
December 2019

Identification and validation of key modules and hub genes associated with the pathological stage of oral squamous cell carcinoma by weighted gene co-expression network analysis.

PeerJ 2020 4;8:e8505. Epub 2020 Feb 4.

Restorative Dental Sciences, Faculty of Dentistry, The University of Hong Kong, Hong Kong SAR, China.

Background: Oral squamous cell carcinoma (OSCC) is a major lethal malignant cancer of the head and neck region, yet its molecular mechanisms of tumourigenesis are still unclear.

Patients And Methods: We performed weighted gene co-expression network analysis (WGCNA) on RNA-sequencing data with clinical information obtained from The Cancer Genome Atlas (TCGA) database. The relationship between co-expression modules and clinical traits was investigated by Pearson correlation analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7717/peerj.8505DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006519PMC
February 2020

Notch Intracellular Domain (NICD) Expression and Clinical Manifestations of Second Primary Tumor at Esophagus in Patients with Head and Neck Squamous Cell Carcinoma.

Onco Targets Ther 2019 17;12:11175-11181. Epub 2019 Dec 17.

Section for Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Introduction: Second primary tumor (SPT) is a major factor that affects the survival of head and neck squamous cell carcinoma (HNSCC) patients, and the esophagus is a common site. Detection of SPT is essential for optimal HNSCC treatment planning and follow-up. Mutation of the gene is common in head and neck cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S227745DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925551PMC
December 2019
1.342 Impact Factor

miR-424-5p Promotes Proliferation, Migration and Invasion of Laryngeal Squamous Cell Carcinoma.

Onco Targets Ther 2019 29;12:10441-10453. Epub 2019 Nov 29.

Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.

Background: Recent studies revealed that miR-424-5p regulates the malignant behavior of multiple cancer types. However, the expression and function of miR-424-5p in laryngeal squamous cell carcinoma (LSCC) is unclear.

Purpose: This study aimed to evaluate the association of miR-424-5p level with clinical features of LSCC and investigate the effect and potential mechanism of miR-424-5p on LSCC progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S224325DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890199PMC
November 2019

A High-Content Screening Approach to Identify MicroRNAs Against Head and Neck Cancer Cell Survival and EMT in an Inflammatory Microenvironment.

Front Oncol 2019 8;9:1100. Epub 2019 Nov 8.

Center for Cell-Based Therapy (CTC), Regional Blood Center of Ribeirão Preto, Ribeirão Preto, Brazil.

Head and neck squamous cell carcinoma (HNSCC) is among the most common cancer types. Metastasis, the main cause of death by cancer, can be promoted by an inflammatory microenvironment, which induces epithelial-mesenchymal transition (EMT) through a NF-κB-mediated stabilization of Snail. Here, we aimed to explore how microRNAs (miRs) can affect cell survival and EMT in HNSCC cells under an inflammatory microenvironment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.01100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856008PMC
November 2019

Patterns of protein expression in human head and neck cancer cell lines differ after proton vs photon radiotherapy.

Head Neck 2020 Feb 11;42(2):289-301. Epub 2019 Nov 11.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: Proton radiotherapy (PRT) may be a less toxic alternative to photon radiotherapy (XRT) for patients with head and neck squamous cell carcinoma (HNSCC). However, the molecular responses of HNSCC cells to PRT vs XRT are unclear.

Methods: Proteomics analyses of protein expression profiles by reverse-phase protein arrays were done for two human papillomavirus [HPV]-negative and two HPV+ cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.26005DOI Listing
February 2020
2.641 Impact Factor

Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma.

PLoS One 2019 9;14(10):e0223639. Epub 2019 Oct 9.

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America.

Head and neck squamous cell carcinoma (HNSCC) remains a morbid disease with poor prognosis and treatment that typically leaves patients with permanent damage to critical functions such as eating and talking. Currently only three targeted therapies are FDA approved for use in HNSCC, two of which are recently approved immunotherapies. In this work, we identify biological pathways involved with this disease that could potentially be targeted by current FDA approved cancer drugs and thereby expand the pool of potential therapies for use in HNSCC treatment. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0223639PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785123PMC
March 2020
2 Reads

Integrin α-5 as a potential biomarker of head and neck squamous cell carcinoma.

Oncol Lett 2019 Oct 22;18(4):4048-4055. Epub 2019 Aug 22.

Department of Oral and Maxillofacial Surgery, Liaocheng People's Hospital, Medical College of Liaocheng University, Liaocheng, Shandong 252000, P.R. China.

Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignant tumors that endanger human health. In recent years, the incidence of HNSCC has been increasing, without any significant improvement in the prognosis. Therefore, increased knowledge on the molecular mechanism underlying HNSCC development will allow the development of new strategies for therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2019.10773DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757314PMC
October 2019
2 Reads

Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma.

Biomolecules 2019 09 30;9(10). Epub 2019 Sep 30.

College of Korean Medicine, Kyung Hee University, #47, Kyungheedae-gil, Dongdaemoon-gu, Seoul 130-701, Korea.

STAT3 is a latent transcription factor that plays a vital role in the transmission of extracellular signal from receptors to the nucleus. It has been regarded as a master transcription factor due to its role in the regulation of a broad spectrum of genes, which can contribute to oncogenesis. Persistent activation of STAT3 and deregulation of its signaling has been observed in various human cancers including head and neck squamous cell carcinoma (HNSCC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/biom9100550DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843503PMC
September 2019
2 Reads

Using weighted gene co-expression network analysis to identify key modules and hub genes in tongue squamous cell carcinoma.

Medicine (Baltimore) 2019 Sep;98(37):e17100

Department of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang.

Background: Tongue squamous cell carcinoma (TSCC) is one of the most common malignant tumors in head and neck, but its molecular mechanism is not clear.

Methods: Weighted gene co-expression network analysis (WGCNA) combining with gene differential expression analysis, survival analysis to screen key modules and hub genes related to the progress of TSCC. Gene Set Enrichment Analysis (GSEA) was used to identify biological pathways that might be involved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000017100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750333PMC
September 2019
1 Read

The relevance between the immune response-related gene module and clinical traits in head and neck squamous cell carcinoma.

Cancer Manag Res 2019 6;11:7455-7472. Epub 2019 Aug 6.

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, People's Republic of China.

Purpose: Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer in the world, accounting for more than 90% of head and neck malignant tumors. However, its molecular mechanism is largely unknown. To help elucidate the potential mechanism of HNSCC tumorigenesis, we investigated the gene interaction patterns associated with tumorigenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S201177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689548PMC

Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine.

EPMA J 2019 Sep 20;10(3):291-305. Epub 2019 Jul 20.

1Department of Oral Biology and Diagnostic Sciences, The Dental College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912 USA.

Head and neck squamous cell carcinoma (HNSCC) develops in the mucosal lining of the upper aerodigestive tract, principally as a result of exposure to carcinogens present in tobacco products and alcohol, with oncogenic papillomaviruses also being recognized as etiological agents in a limited proportion of cases. As such, there is considerable scope for prevention of disease development and progression. However, despite multimodal approaches to treatment, tumor recurrence and metastatic disease are common problems, and clinical outcome is unsatisfactory. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13167-019-00177-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695454PMC
September 2019
2 Reads

LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus.

J Exp Clin Cancer Res 2019 Aug 20;38(1):365. Epub 2019 Aug 20.

Department of Oral and Maxillofacial-Head & Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, China.

Background: The lncRNA LINC00460 plays crucial roles in several epithelial cancers, although its mechanisms of action differ greatly in different cellular contexts. In this study, we aimed to determine the potential clinical applications of LINC00460 and elucidate the mechanisms by which LINC00460 affects the development and progression of head and neck squamous cell carcinoma (HNSCC).

Methods: The biological functions of LINC00460 were assessed in several epithelial cancer cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1364-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700841PMC
August 2019
5 Reads

Long Non-coding RNAs as Important Biomarkers in Laryngeal Cancer and Other Head and Neck Tumours.

Int J Mol Sci 2019 Jul 12;20(14). Epub 2019 Jul 12.

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80100 Naples, Italy.

Head and neck carcinoma (HNC) is a heterogeneous disease encompassing a variety of tumors according to the origin. Laryngeal cancer (LC) represents one of the most frequent tumors in the head and neck region. Despite clinical studies and advance in treatment, satisfactory curative strategy has not yet been reached. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20143444DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678449PMC
July 2019
1 Read

miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer.

Neoplasia 2019 09 18;21(9):849-862. Epub 2019 Jul 18.

Department of Radiation Oncology, Division of Molecular Radiation Biology, UT Southwestern Medical Center, Dallas, TX 75390. Electronic address:

MicroRNAs (miRNAs) are short single-stranded RNAs, measuring 21 to 23 nucleotides in length and regulate gene expression at the post-transcriptional level through mRNA destabilization or repressing protein synthesis. Dysregulation of miRNAs can lead to tumorigenesis through changes in regulation of key cellular processes such as cell proliferation, cell survival, and apoptosis. miR-125a-5p has been implicated as a tumor suppressor miRNA in malignancies such as non-small cell lung cancer and colon cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2019.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642270PMC
September 2019
4 Reads

Bioinformatics-based discovery of PYGM and TNNC2 as potential biomarkers of head and neck squamous cell carcinoma.

Authors:
Yu Jin Ya Yang

Biosci Rep 2019 07 29;39(7). Epub 2019 Jul 29.

Department of General Dentistry, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China

Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy with high morbidity and mortality rates and ranks as the sixth most common cancer all over the world. Despite numerous advancements in therapeutic methods, the prognosis of HNSCC patients still remains poor. Therefore, there is an urgent need to have a better understanding of the molecular mechanisms underlying HNSCC progression and to identify essential genes that could serve as effective biomarkers and potential treatment targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BSR20191612DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663994PMC
July 2019
1 Read

Identification and analysis of genes associated with head and neck squamous cell carcinoma by integrated bioinformatics methods.

Authors:
Yu Jin Ya Yang

Mol Genet Genomic Med 2019 08 15;7(8):e857. Epub 2019 Jul 15.

Department of General Dentistry, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.

Background: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide, exhibiting high morbidity and mortality. The prognosis of HNSCC patients has remained poor, though considerable efforts have been made to improve the treatment of this cancer. Therefore, identifying significant differentially expressed genes (DEGs) involved in HNSCC progression and exploiting them as novel biomarkers or potential therapeutic targets for HNSCC is highly valuable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mgg3.857DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687648PMC
August 2019
1 Read

Sorting Nexin 5 Controls Head and Neck Squamous Cell Carcinoma Progression by Modulating FBW7.

J Cancer 2019 2;10(13):2942-2952. Epub 2019 Jun 2.

Philips Institute for Oral Health Research, School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.

Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide. Long-term survival rates in patients with HNSCC have not increased significantly in the past 30 years. Therefore, looking for novel molecular targets that control HNSCC progression is urgently required to improve the treatment of HNSCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.31055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590026PMC

Analysis of methylation-driven genes for predicting the prognosis of patients with head and neck squamous cell carcinoma.

J Cell Biochem 2019 12 1;120(12):19482-19495. Epub 2019 Jul 1.

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

To help provide evidence for prognosis prediction and personalized targeted therapy for patients with head and neck squamous cell carcinoma (HNSCC), we investigated prognosis-specific methylation-driven genes in HNSCC. Survival time data, RNA sequencing data, and methylation data for HNSCC patients were downloaded from The Cancer Genome Atlas. The MethylMix R package based on the β mixture model was utilized to screen genes with different methylation statuses in tumor tissues and adjacent normal tissues, and a total of 182 HNSCC-related methylation-driven genes were then identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.29252DOI Listing
December 2019
3 Reads
3.263 Impact Factor

MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1.

J Exp Clin Cancer Res 2019 Jun 28;38(1):281. Epub 2019 Jun 28.

National Institute of Cancer Research, National Health Research Institutes, No. 35 Keyan Road, Zhunan Town, Miaoli County, 35053, Taiwan.

Background: Discoidin domain receptor-1 (DDR1) tyrosine kinase is highly expressed in a variety of human cancers and involved in various steps of tumorigenesis. However, the precise mechanisms underlying the abnormal expression of DDR1 in oral squamous cell carcinoma (OSCC) has not been well investigated.

Methods: The expression of DDR1 on OSCC patients was determine by quantitative real-time PCR (qRT-PCR) and immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1283-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599238PMC
June 2019
4 Reads

Short-term RANKL exposure initiates a neoplastic transcriptional program in the basal epithelium of the murine salivary gland.

Cytokine 2019 11 18;123:154745. Epub 2019 Jun 18.

Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. Electronic address:

Although salivary gland cancers comprise only ∼3-6% of head and neck cancers, treatment options for patients with advanced-stage disease are limited. Because of their rarity, salivary gland malignancies are understudied compared to other exocrine tissue cancers. The comparative lack of progress in this cancer field is particularly evident when it comes to our incomplete understanding of the key molecular signals that are causal for the development and/or progression of salivary gland cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cyto.2019.154745DOI Listing
November 2019
5 Reads

Downregulation of GBAS regulates oral squamous cell carcinoma proliferation and apoptosis via the p53 signaling pathway.

Onco Targets Ther 2019 17;12:3729-3742. Epub 2019 May 17.

Department of Oral Medicine, Peking University School and Hospital of Stomatology, Beijing, People's Republic of China.

Oral squamous cell carcinoma (OSCC) is the most common and severe type of head and neck malignancy. The mechanisms by which OSCC arises depend on changes in a number of different factors and genes and the clinicopathological stage of the tumors. Better understanding the possible mechanisms of OSCC would help to identify a new target for molecular targeted therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S207930DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529179PMC
May 2019
4 Reads

Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer.

Int J Cancer 2019 12 19;145(12):3299-3310. Epub 2019 Jun 19.

Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany.

Genomic sequencing projects unraveled the mutational landscape of head and neck squamous cell carcinoma (HNSCC) and provided a comprehensive catalog of somatic mutations. However, the limited number of significant cancer-related genes obtained so far only partially explains the biological complexity of HNSCC and hampers the development of novel diagnostic biomarkers and therapeutic targets. We pursued a multiscale omics approach based on whole-exome sequencing, global DNA methylation and gene expression profiling data derived from tumor samples of the HIPO-HNC cohort (n = 87), and confirmed new findings with datasets from The Cancer Genome Atlas (TCGA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32481DOI Listing
December 2019
10 Reads

Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer.

J Natl Cancer Inst 2020 Mar;112(3):266-277

Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.

Background: Alterations in the epidermal growth factor receptor and PI3K pathways in head and neck squamous cell carcinomas (HNSCCs) are frequent events that promote tumor progression. Ectopic expression of the epidermal growth factor receptor-targeting microRNA (miR), miR-27a* (miR-27a-5p), inhibits tumor growth. We sought to identify mechanisms mediating repression of miR-27a* in HNSCC, which have not been previously identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djz097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073912PMC
March 2020
9 Reads

Integrated miRNA and mRNA expression analysis uncovers drug targets in laryngeal squamous cell carcinoma patients.

Oral Oncol 2019 06 29;93:76-84. Epub 2019 Apr 29.

Department of Surgery and Orthopedics, Faculty of Medicine, São Paulo State University - UNESP, Botucatu, SP, Brazil; Department of Clinical Genetics, Vejle Hospital, Institute of Regional Health Research, University of Southern Denmark, Denmark. Electronic address:

Objectives: The current treatment of laryngeal squamous cell carcinoma (LSCC) is based on radical surgery and radiotherapy resulting in high morbidity. Chemoradiotherapy has been used as alternative to organ sparing; however, several advanced cases presented resistance to treatment, which contributes to a high risk of recurrence and mortality. Coding RNAs and miRNAs have potential to be used as biomarkers or targets for cancer therapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13688375193012
Publisher Site
http://dx.doi.org/10.1016/j.oraloncology.2019.04.018DOI Listing
June 2019
11 Reads

Inhibition of CBP/β-catenin and porcupine attenuates Wnt signaling and induces apoptosis in head and neck carcinoma cells.

Cell Oncol (Dordr) 2019 Aug 14;42(4):505-520. Epub 2019 May 14.

Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, ul. Święcickiego 4, 60-781, Poznań, Poland.

Purpose: Activation of the Wnt pathway contributes to the development of head and neck squamous cell carcinomas (HNSCC) and its inhibition has recently emerged as a promising therapeutic strategy. Here, we aimed at identifying suitable molecular targets for down-regulation of canonical Wnt signaling in HNSCC cells.

Methods: Candidate target genes (PORCN, WNT3A, FZD2, FZD5, LRP5, DVL1, CIP2A, SET, KDM1A, KDM4C, KDM6A, CBP, CARM1, KMT2A, TCF7, LEF1, PYGO1, XIAP) were silenced using siRNA and selected targets were subsequently blocked using small molecule inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13402-019-00440-4DOI Listing
August 2019
3 Reads

Targeting the unfolded protein response in head and neck and oral cavity cancers.

Exp Cell Res 2019 09 7;382(1):111386. Epub 2019 May 7.

Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA; Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA; Children's Hospital of Michigan, Detroit Medical Center, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA. Electronic address:

Many FDA-approved anti-cancer therapies, targeted toward a wide array of molecular targets and signaling networks, have been demonstrated to activate the unfolded protein response (UPR). Despite a critical role for UPR signaling in the apoptotic execution of cancer cells by many of these compounds, the authors are currently unaware of any instance whereby a cancer drug was developed with the UPR as the intended target. With the essential role of the UPR as a driving force in the genesis and maintenance of the malignant phenotype, a great number of pre-clinical studies have surged into the medical literature describing the ability of dozens of compounds to induce UPR signaling in a myriad of cancer models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2019.04.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867800PMC
September 2019
7 Reads

AlloDriver: a method for the identification and analysis of cancer driver targets.

Nucleic Acids Res 2019 07;47(W1):W315-W321

Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Clinical and Fundamental Research Center, Department of Pharmacy, Renji Hospital, Shanghai Jiao-Tong University School of Medicine (SJTU-SM), Shanghai 200127, China.

Identifying the variants that alter protein function is a promising strategy for deciphering the biological consequences of somatic mutations during tumorigenesis, which could provide novel targets for the development of cancer therapies. Here, based on our previously developed method, we present a strategy called AlloDriver that identifies cancer driver genes/proteins as possible targets from mutations. AlloDriver utilizes structural and dynamic features to prioritize potentially functional genes/proteins in individual cancers via mapping mutations generated from clinical cancer samples to allosteric/orthosteric sites derived from three-dimensional protein structures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gkz350DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602569PMC
July 2019
50 Reads
9.112 Impact Factor

Targeted Therapy Against the Cell of Origin in Cutaneous Squamous Cell Carcinoma.

Int J Mol Sci 2019 May 5;20(9). Epub 2019 May 5.

Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia.

Squamous cell carcinomas (SCC), including cutaneous SCCs, are by far the most frequent cancers in humans, accounting for 80% of all newly diagnosed malignancies worldwide. The old dogma that SCC develops exclusively from stem cells (SC) has now changed to include progenitors, transit-amplifying and differentiated short-lived cells. Accumulation of specific oncogenic mutations is required to induce SCC from each cell population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20092201DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539622PMC
May 2019
1 Read

Wnt Signaling: A Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma

Asian Pac J Cancer Prev 2019 Apr 29;20(4):995-1003. Epub 2019 Apr 29.

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

Cellular maintenance and development are two fundamental mechanisms regulated by the canonical Wnt signaling pathway. Wnt/beta-catenin signaling pathway controls a myriad of cellular processes that are essential for normal cell functioning. Cell cycle progression, differentiation, fate determination, and migration are generally orchestrated by canonical Wnt signaling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31557/APJCP.2019.20.4.995DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948882PMC
April 2019
5 Reads
1.500 Impact Factor

Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy.

Front Cell Dev Biol 2019 9;7:52. Epub 2019 Apr 9.

Department of Biochemistry and Molecular Biology, Georgia Cancer Center, School of Medicine, Augusta University, Augusta, GA, United States.

Head and neck squamous cell carcinomas (HNSCCs) are highly aggressive, multi-factorial tumors in the upper aerodigestive tract affecting more than half a million patients worldwide each year. Alcohol, tobacco, and human papillomavirus (HPV) infection are well known causative factors for HNSCCs. Current treatment options for HNSCCs are surgery, radiotherapy, chemotherapy, or combinatorial remedies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fcell.2019.00052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465325PMC
April 2019
7 Reads

Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas.

Cells 2019 04 21;8(4). Epub 2019 Apr 21.

Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland.

Background: Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease with high mortality. The identification of specific HNSCC biomarkers will increase treatment efficacy and limit the toxicity of current therapeutic strategies. Long non-coding RNAs (lncRNAs) are promising biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells8040366DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523746PMC
April 2019
6 Reads

Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy.

Cancers (Basel) 2019 Mar 29;11(4). Epub 2019 Mar 29.

Division of Cell Biology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.

About half of advanced stage head and neck squamous cell carcinoma (HNSCC) patients can be cured by chemoradiotherapy. Patient outcome may be partially determined by the genetic alterations in HNSCC, rendering these alterations promising candidate prognostic factors and/or therapeutic targets. However, their relevance in patient outcome prognosis remains to be assessed in patients that receive standard-of-care chemoradiotherapy. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/2072-6694/11/4/445
Publisher Site
http://dx.doi.org/10.3390/cancers11040445DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521057PMC
March 2019
22 Reads

Identification of novel diagnostic markers for sinonasal undifferentiated carcinoma.

Head Neck 2019 08 1;41(8):2688-2695. Epub 2019 Apr 1.

Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: Sinonasal undifferentiated carcinoma (SNUC) is a rare, highly aggressive cancer. It is often difficult to determine whether SNUC is a distinct pathologic entity with poorly differentiated neuroendocrine features or it represents an undifferentiated tumor of squamous lineage. Also, reliable histopathologic markers that distinguish SNUC from poorly differentiated sinonasal squamous cell carcinoma (SNSCC) are lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.25748DOI Listing
August 2019
10 Reads

miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells.

J Exp Clin Cancer Res 2019 Mar 29;38(1):141. Epub 2019 Mar 29.

Oncogenomics and Epigenetics Unit, IRCCS-Regina Elena National Cancer Institute, 00144, Rome, Italy.

Background: Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer worldwide. They are typically characterized by a high incidence of local recurrence, which is the most common cause of death in HNSCC patients. TP53 is the most frequently mutated gene in HNSCC and patients carrying TP53 mutations are associated with a higher probability to develop local recurrence. Read More

View Article

Download full-text PDF

Source
https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-
Publisher Site
http://dx.doi.org/10.1186/s13046-019-1119-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440033PMC
March 2019
27 Reads

Drug repositioning in head and neck squamous cell carcinoma: An integrated pathway analysis based on connectivity map and differential gene expression.

Pathol Res Pract 2019 Jun 5;215(6):152378. Epub 2019 Mar 5.

Department of Otolaryngology Head and Neck Surgery, NO.303 Hospital of PLA, Nanning, Guangxi Zhuang Autonomous Region, China. Electronic address:

The severe damage to health and social burden caused by head and neck squamous cell carcinoma (HNSCC) generated an urgent need to develop novel anti-cancer therapy. Currently, drug repositioning has risen in responses to the proper time as an efficient approach to invention of new anti-cancer therapies. In the present study, we aimed to screen candidate drugs for HNSCC by integrating HNSCC-related pathways from differentially expressed genes (DEGs) and drug-affected pathways from connectivity map (CMAP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2019.03.007DOI Listing
June 2019
9 Reads

Functional genomics screen with pooled shRNA library and gene expression profiling with extracts of identify potential pathways for therapeutic targets in head and neck squamous cell carcinoma.

PeerJ 2019 1;7:e6464. Epub 2019 Mar 1.

Ganit Labs, Bio-IT Centre, Institute of Bioinformatics and Applied Biotechnology, Bangalore, India.

Tumor suppression by the extracts of (neem) works via anti-proliferation, cell cycle arrest, and apoptosis, demonstrated previously using cancer cell lines and live animal models. However, very little is known about the molecular targets and pathways that neem extracts and their associated compounds act through. Here, we address this using a genome-wide functional pooled shRNA screen on head and neck squamous cell carcinoma cell lines treated with crude neem leaf extracts, known for their anti-tumorigenic activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7717/peerj.6464DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398373PMC
March 2019
2 Reads

Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets.

Front Oncol 2019 13;9:74. Epub 2019 Feb 13.

Department of Drug Development & Innovation (D3i), Institut Curie, Paris, France.

Although the molecular landscape of squamous cell carcinoma of the head and neck (SCCHN) has been largely deciphered, only one targeted therapy has been approved to date without any molecular selection, namely cetuximab. Cetuximab is a monoclonal antibody targeting EGFR. It has been shown to improve overall survival in the locally advanced setting in combination with radiotherapy and the recurrent and/or metastatic setting in combination with a platinum compound and 5FU. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00074DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381014PMC
February 2019
3 Reads

Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α.

Br J Cancer 2019 03 15;120(6):658-667. Epub 2019 Feb 15.

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.

Background: Epidermal growth factor receptor (EGFR) overexpression is associated with the development of head and neck cancer (HNC) and represents one of the main therapeutic targets for this disease. The use of EGFR inhibitors has limited efficacy due to their primary and acquired resistance, partially because of increased epithelial to mesenchymal transition (EMT). The HDAC inhibitor SAHA has been shown to revert EMT in different tumours, including HNC. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0394-9
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0394-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461861PMC
March 2019
7 Reads

Expression of USP22 and the chromosomal passenger complex is an indicator of malignant progression in oral squamous cell carcinoma.

Oncol Lett 2019 Feb 17;17(2):2040-2046. Epub 2018 Dec 17.

Department of Pathology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China.

Oral cancer is a common cancer of the head and neck. Oral squamous cell carcinoma (OSCC) represents almost 90% of the total cases of head and neck cancer. Ubiquitin-specific protease 22 (USP22) is a deubiquitinating hydrolase, and it is highly expressed in various types of cancer, which also typically have a poor prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2018.9837DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341666PMC
February 2019
3 Reads

Integrated analyses utilizing metabolomics and transcriptomics reveal perturbation of the polyamine pathway in oral cavity squamous cell carcinoma.

Anal Chim Acta 2019 Mar 2;1050:113-122. Epub 2018 Nov 2.

Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan; Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Otolaryngology - Head & Neck Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan; Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address:

Oral cavity squamous cell carcinoma (OSCC), the most common malignancy of the oral cavity, is associated with poor prognosis and high mortality worldwide. Moreover, knowledge of the metabolic alterations that occur in OSCC is still limited. In the present study, we used a quantitative metabolomic approach with chemical isotope labeling (CIL) to analyze alterations in the metabolite levels in paired cancerous (T) and adjacent noncancerous (AN) tissues from 31 OSCC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aca.2018.10.070DOI Listing
March 2019
23 Reads

Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments.

Oncogene 2019 05 17;38(19):3551-3568. Epub 2019 Jan 17.

Molecular and Human Genetics Department, Baylor College of Medicine, Houston, TX, USA.

Although head and neck squamous cell carcinoma (HNSCC) has in the past been largely associated with tobacco use, human papillomavirus (HPV+) oropharynx cancer has in recent years emerged as the fastest growing type of HNSCC. Patients with HPV+ HNSCC have a better prognosis; however, the 5-year survival for both HPV+ and HPV- subtypes with recurrent or metastatic disease is poor. To gain insights into the tumor microenvironments of both HNSCC subtypes and identify potential therapeutic targets, we performed epigenomic deconvolution on 580 HNSCC samples from the TCGA dataset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-018-0659-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756123PMC
May 2019
3 Reads

The effect of 2D and 3D cell cultures on treatment response, EMT profile and stem cell features in head and neck cancer.

Cancer Cell Int 2019 14;19:16. Epub 2019 Jan 14.

1Division of Cell Biology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.

Background: Head and Neck Squamous Cell Carcinoma (HNSCC) tumors are often resistant to therapies. Therefore searching for predictive markers and new targets for treatment in clinically relevant in vitro tumor models is essential. Five HNSCC-derived cell lines were used to assess the effect of 3D culturing compared to 2D monolayers in terms of cell proliferation, response to anti-cancer therapy as well as expression of EMT and CSC genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0733-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332598PMC
January 2019
22 Reads

Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses.

BMC Cancer 2019 Jan 14;19(1):64. Epub 2019 Jan 14.

Department of Radiation Oncology, Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan.

Background: Radiotherapy is an indispensable treatment modality in head and neck cancer (HNC), while radioresistance is the major cause of treatment failure. The aim of this study is to identify a prognostic molecular signature associated with radio-resistance in HNC for further clinical applications.

Methods: Affymetrix cDNA microarrays were used to globally survey different transcriptomes between HNC cell lines and isogenic radioresistant sublines. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-018-5243-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332600PMC
January 2019
10 Reads
3.362 Impact Factor

Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.

Oral Oncol 2019 01 20;88:29-38. Epub 2018 Nov 20.

Medical Oncology Department, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS) & Université Paris 7, Paris, France. Electronic address:

The microenvironment of solid tumors has become a promising target for future therapies modulating immune cells. Patients with advanced head and neck cancer, which still portends a poor outcome, are particularly in need of innovative approaches. In oral squamous cell carcinoma, high density of tumor-associated macrophages (TAMs) appears consistently associated with poor prognosis, whereas data are currently limited for other head and neck sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2018.10.040DOI Listing
January 2019
2 Reads

Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis.

Onco Targets Ther 2018 30;11:7529-7542. Epub 2018 Oct 30.

Department of Oncology, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei, People's Republic of China,

We conducted a meta-analysis to estimate the impact of different clinical and molecular characteristics on the efficacy of programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors. PubMed and Web of Science were searched for related trials. Eleven eligible studies, comprising 5,663 patients, were included in this meta-analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S167865DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214579PMC
October 2018
43 Reads

Cortactin expression: Association with disease progression and survival in oral squamous cell carcinoma.

Head Neck 2018 12 20;40(12):2685-2694. Epub 2018 Nov 20.

Department of Oral and Cranio-Maxillofacial Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Background: Cortactin (CTTN) is located on chromosome 11q13 and is associated with invasiveness in various cancer entities. CTTN protein expression could be a prognosticator of oral squamous cell carcinoma (OSCC) in terms of recurrence and survival.

Methods: CTTN-dependent invasion was performed using migration assay in human papillomavirus-negative head and neck squamous cell carcinoma (HNSCC) cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.25515DOI Listing
December 2018
10 Reads

lncRNA Expression after Irradiation and Chemoexposure of HNSCC Cell Lines.

Noncoding RNA 2018 Nov 14;4(4). Epub 2018 Nov 14.

Laboratory of Cancer Genetics, Greater Poland Cancer Centre, 61-866 Poznan, Poland.

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer mortality in the world. To improve the quality of diagnostics and patients' treatment, new and effective biomarkers are needed. Recent studies have shown that the expression level of different types of long non-coding RNAs (lncRNAs) is dysregulated in HNSCC and correlates with many biological processes. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2311-553X/4/4/33
Publisher Site
http://dx.doi.org/10.3390/ncrna4040033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315432PMC
November 2018
34 Reads

Vimentin and Non-Muscle Myosin IIA are Members of the Neural Precursor Cell Expressed Developmentally Down-Regulated 9 (NEDD9) Interactome in Head and Neck Squamous Cell Carcinoma Cells.

Transl Oncol 2019 Jan 26;12(1):49-61. Epub 2018 Sep 26.

Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, 173 Ashley Avenue MSC 509, Charleston, SC 29425-5050; Hollings Cancer Center, Medical University of South Carolina, 173 Ashley Avenue MSC 550, Charleston, SC 29425-5050. Electronic address:

Here we demonstrate an interaction between neural precursor cell expressed, developmentally-downregulated 9 (NEDD9) and the cytoskeletal proteins vimentin and non-muscle myosin IIA (NMIIA), based on co-immunoprecipitation and mass spectrometric sequence identification. Vimentin was constitutively phosphorylated at Ser56 but vimentin associated with NEDD9-was not phosphorylated at Ser56. In contrast, NMIIA bound to NEDD9 was phosphorylated on S1943 consistent with its function in invasion and secretion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2018.09.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160858PMC
January 2019
1 Read